LLY collapsed to $903.48 (RSI 30.0 — entering extreme oversold, -10.5% 30D). TMO $472.83 (RSI 33.7 — still oversold, -7.4% 30D). BNTX $87.69 (RSI 35.5, down trend, -20.4% 30D). CRSP $46.40 (RSI 36.8, strong-down, -13.2% 30D). VRTX $455.65 (RSI 43.6, weak-down — lost golden cross momentum). MRNA $51.39 (RSI 51.4, strong-up, GC — still the lone bright spot). NTLA $13.01 (RSI 49, strong-up).
Quick Snapshot
| Signal |
Reading |
| Overall |
🔴 SECTOR DETERIORATING — LLY NOW JOINING OVERSOLD CLUB — LLY $903.48 RSI 30.0, -10.5% 30D — GLP-1 leader cracking below $900 approaching extreme oversold. TMO RSI 33.7 oversold but not recovering. BNTX -20.4% 30D. Only MRNA RSI 51.4 strong-up and NTLA RSI 49 hold structural positives. |
| Key insight |
LLY $903.48 RSI 30.0 — GLP-1 giant now at oversold threshold, -20.3% from 52wk high. TMO RSI 33.7 flat — no bounce in life sciences tools despite extreme oversold. MRNA $51.39 RSI 51.4 strong-up golden cross the only real winner. |
Action Matrix
| Action |
Stocks |
Why |
| ✅ BUY |
LLY |
$903.48, RSI 30.0 — GLP-1 leader at extreme oversold, -20.3% from high |
| 🔍 RESEARCH |
TMO |
$472.83, RSI 33.7 — Thermo Fisher still at capitulation levels |
| 🔍 RESEARCH |
BNTX |
$87.69, RSI 35.5, -20.4% 30D — mRNA pioneer deeply oversold |
| 🔍 WATCH |
CRSP |
$46.40, RSI 36.8 — gene editing weak, strong-down death cross |
| 🔍 WATCH |
VRTX |
$455.65, RSI 43.6 — golden cross fading, pulling back |
| 🔒 HOLD |
MRNA |
$51.39, RSI 51.4 — strong-up, golden cross, recovery intact |
| 🔒 HOLD |
NTLA |
$13.01, RSI 49 — near SMA, strong-up |
Data (Validated 2026-03-20)
| Stock |
Price |
7D |
30D |
52wkHi |
RSI |
SMA20 |
vs SMA |
Status |
Action |
| LLY |
$903.48 |
-7.8% |
-10.5% |
-20.3% |
30.0 |
$991.83 |
-8.9% |
🔴 Oversold extreme |
✅ Buy |
| TMO |
$472.83 |
-0.1% |
-7.4% |
-26.6% |
33.7 |
$496.33 |
-4.7% |
🔴 Extreme oversold, no bounce |
🔍 Research |
| BNTX |
$87.69 |
-1.7% |
-20.4% |
-29.1% |
35.5 |
$98.79 |
-11.2% |
🔴 Oversold, declining |
🔍 Research |
| CRSP |
$46.40 |
-4.5% |
-13.2% |
-40.9% |
36.8 |
$53.96 |
-14.0% |
🔴 Strong-down, death cross |
🔍 Watch |
| VRTX |
$455.65 |
-3.4% |
-4.5% |
-11.3% |
43.6 |
$473.90 |
-3.9% |
🟡 Weak-down, golden cross |
🔍 Watch |
| NTLA |
$13.01 |
+0.3% |
+2.9% |
-53.6% |
49.0 |
$13.49 |
-3.6% |
🟢 Strong-up |
🔒 Hold |
| MRNA |
$51.39 |
-2.8% |
+3.0% |
-13.6% |
51.4 |
$53.02 |
-3.1% |
🟢 Strong-up, golden cross |
🔒 Hold |
Key Changes vs 03/13
| Stock |
03/13 Price |
03/20 Price |
Move |
Note |
| LLY |
$985.28 |
$903.48 |
-8.3% |
RSI 43 → 30.0 — entering extreme oversold territory |
| BNTX |
$88.80 |
$87.69 |
-1.2% |
RSI 33 → 35.5 — slight stabilization but -20.4% 30D |
| TMO |
$464.38 |
$472.83 |
+1.8% |
RSI 24 → 33.7 — slight bounce from extreme oversold |
| MRNA |
$52.56 |
$51.39 |
-2.2% |
RSI 56 → 51.4 — slight pullback, strong-up intact |
| VRTX |
$485.55 |
$455.65 |
-6.2% |
RSI 54 → 43.6 — significant deterioration |
Key Discoveries
| Discovery |
Implication |
| LLY RSI 30.0, -10.5% 30D — below $900 |
GLP-1 market leader at rare oversold extreme — thesis unchanged, entry zone forming |
| TMO tiny bounce (+1.8%) from RSI 24 to 33.7 |
Life sciences tools finding a floor — but no conviction reversal yet |
| VRTX deteriorated RSI 54 → 43.6 |
CF therapy leader losing momentum — watch SMA200 for support |
Open Questions
- LLY RSI 30 — is $900 the floor or does $850 come into play?
- TMO RSI 33.7 — real capitulation bounce or dead-cat?
- CRSP strong-down death cross — is gene editing structurally broken?